Company Overview
| Stock Name | Euroeyes |
|---|---|
| Stock Code | 01846 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 在德國、丹麥及中國提供視力矯正服務,包括屈光性激光手術、後房型人工晶體(ICL)植入術、晶體置換手術及其他。 |
| Listing Date | 2019-10-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港銅鑼灣羅素街2-4號2000年廣場 3樓 |
| Business Address (Hong Kong) | 香港銅鑼灣勿地臣街1號時代廣場二座3711室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | euroeyes.hk |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 7.50 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2019-09-30 to 2019-10-08 |
| Global Offering Shares | 79,334,000 shares |
| HK Public Offer Shares (Initial) | 7,934,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 71,400,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 317,334,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 595,005,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 7,500 |
| 2 lots | 2,000 | HK$ 15,000 |
| 3 lots | 3,000 | HK$ 22,500 |
| 4 lots | 4,000 | HK$ 30,000 |
| 5 lots | 5,000 | HK$ 37,500 |
| 6 lots | 6,000 | HK$ 45,000 |
| 7 lots | 7,000 | HK$ 52,500 |
| 8 lots | 8,000 | HK$ 60,000 |
| 9 lots | 9,000 | HK$ 67,500 |
| 10 lots | 10,000 | HK$ 75,000 |
| 15 lots | 15,000 | HK$ 112,500 |
| 20 lots | 20,000 | HK$ 150,000 |
| 25 lots | 25,000 | HK$ 187,500 |
| 30 lots | 30,000 | HK$ 225,000 |
| 35 lots | 35,000 | HK$ 262,500 |
| 40 lots | 40,000 | HK$ 300,000 |
| 45 lots | 45,000 | HK$ 337,500 |
| 50 lots | 50,000 | HK$ 375,000 |
| 60 lots | 60,000 | HK$ 450,000 |
| 70 lots | 70,000 | HK$ 525,000 |
| 80 lots | 80,000 | HK$ 600,000 |
| 90 lots | 90,000 | HK$ 675,000 |
| 100 lots | 100,000 | HK$ 750,000 |
| 150 lots | 150,000 | HK$ 1,125,000 |
| 200 lots | 200,000 | HK$ 1,500,000 |
| 250 lots | 250,000 | HK$ 1,875,000 |
| 300 lots | 300,000 | HK$ 2,250,000 |
| 350 lots | 350,000 | HK$ 2,625,000 |
| 400 lots | 400,000 | HK$ 3,000,000 |
| 450 lots | 450,000 | HK$ 3,375,000 |
| 500 lots | 500,000 | HK$ 3,750,000 |
| 600 lots | 600,000 | HK$ 4,500,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 700 lots | 700,000 | HK$ 5,250,000 |
| 800 lots | 800,000 | HK$ 6,000,000 |
| 900 lots | 900,000 | HK$ 6,750,000 |
| 1,000 lots | 1,000,000 | HK$ 7,500,000 |
| 1,500 lots | 1,500,000 | HK$ 11,250,000 |
| 2,000 lots | 2,000,000 | HK$ 15,000,000 |
| 2,500 lots | 2,500,000 | HK$ 18,750,000 |
| 3,000 lots | 3,000,000 | HK$ 22,500,000 |
| 3,500 lots | 3,500,000 | HK$ 26,250,000 |
| 3,967 lots | 3,967,000 | HK$ 29,752,500 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 791.8M |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +1093% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約4.3百萬歐元 |
| Period-End Cash Balance | 歐元16.6百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2016 | 2017 | 2018 |
|---|---|---|---|
| Revenue | 30,402 | 36,977 | 42,961 |
| Cost of sales | -20,485 | -23,848 | -25,545 |
| Gross profit | 9,917 | 13,129 | 17,416 |
| Other income and gains, net | 194 | 8,283 | 238 |
| Selling and distribution expenses | -4,567 | -5,676 | -5,529 |
| Administrative expenses | -1,569 | -1,745 | -3,883 |
| Operating profit | 3,965 | 13,996 | 8,156 |
| Net finance costs | -787 | -1,267 | -825 |
| Profit before tax | 3,178 | 12,729 | 7,331 |
| Income tax expense | -1,239 | -4,158 | -3,040 |
| Profit for the year | 1,939 | 8,571 | 4,291 |
| Profit attributable to owners | 2,376 | 8,707 | 3,833 |
Balance Sheet
| Item | 2016 | 2017 | 2018 | 2019-03 |
|---|---|---|---|---|
| Cash and cash equivalents | 5,396 | 6,556 | 16,558 | |
| Trade and bills receivables | 411 | 327 | 517 | |
| Inventories | 1,236 | 1,692 | 3,458 | |
| Total current assets | 8,462 | 18,571 | 23,909 | |
| Total assets | 39,839 | 48,277 | 65,943 | |
| Total current liabilities | 13,412 | 15,769 | 16,862 | |
| Total liabilities | 28,000 | 27,356 | 39,268 | |
| Total equity | 11,839 | 20,921 | 26,675 | |
| Equity attributable to owners | 10,921 | 19,993 | 25,288 | |
| Interest-bearing borrowings | 2,136 | 2,335 | 48 | 533 |
Cash Flow Statement
| Item | 2016 | 2017 | 2018 | 2019-03 |
|---|---|---|---|---|
| Net cash from operating activities | -342 | 8,850 | 17,495 | |
| Net cash from investing activities | -2,362 | -3,959 | -2,130 | |
| Net cash from financing activities | -1,426 | -3,645 | -5,380 | |
| Net increase in cash | -4,130 | 1,246 | 9,985 | |
| Purchase of PP&E | -1,505 | -4,057 | -2,220 | -874 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 11.0 |
|---|---|
| First Day Open | HK$ 14.2 |
| First Day Change | 46.67% |
| First Day Volume | 99111000.0 |
| First Day Turnover | 1248930000.0 |
| Use of Proceeds | 1、約210.7百萬港元(占估計所得款項凈額總數的約40.0%)用于在中國主要城市(包括成都和重慶)設立診所;
2、約173.8百萬港元(占估計所得款項凈額總數的約33.0%)用于可能收購歐洲的診所集團;
3、約89.5百萬港元(占估計所得款項凈額總數的約17.0%)用于加大我們的營銷力度;
4、約52.7百萬港元(占估計所得款項凈額總數的約10.0%)用于我們的營運資金及用于一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中银国际亚洲有限公司 CE AET863
Overall Coordinators (1)
中银国际亚洲有限公司 CE AET863
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | Jørn Slot Jørgensen | — |
| Company Secretary | 梁庭彰 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Jørgensen醫生持股52.84%,Susanne Jørgensen醫生(配偶權益)持股52.84%;靈銳國際持股7.28%,由CHINAEYES Limited、TOPGOOD Inc.、AIRUIKANG Holdings Limited及徐旭陽先生最終持有。 |
|---|




